Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
7.07
+0.04 (0.57%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Grifols Revenue
In the year 2024, Grifols had annual revenue of 7.21B EUR with 9.41% growth. Grifols had revenue of 1.98B in the quarter ending December 31, 2024, with 11.66% growth.
Revenue (ttm)
7.21B EUR
Revenue Growth
+9.41%
P/S Ratio
0.76
Revenue / Employee
303,846 EUR
Employees
23,737
Market Cap
5.68B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.21B | 620.41M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
GRFS News
- 11 days ago - IBL International collaborates with Grifols on advanced biomarker panels - Business Wire
- 17 days ago - Brookfield resumes Grifols takeover talks, El Confidencial reports - Reuters
- 7 weeks ago - Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale - Seeking Alpha
- 7 weeks ago - Grifols expects to boost revenue and free cash flow, shares soar - Reuters
- 7 weeks ago - Grifols' sales rise over 10% in 2024, above target - Reuters
- 2 months ago - Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition - GlobeNewsWire
- 3 months ago - Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease - GlobeNewsWire
- 3 months ago - Mason Capital complains about Grifols' transparency to Spanish regulator - Reuters